EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Pretreatment and Posttreatment Tumor Metabolic Activity Assessed by FDG-PET/CT as Predictors of Tumor Recurrence and Survival Outcomes in Early-Stage Non-Small Cell Lung Cancer Treated With Stereotactic Body Radiation Therapy

Saarang R Deshpande, Tarun K Podder, William Grubb, Yuxia Zhang, Yiran Zheng, Christopher Towe, Philip Linden, Norbert Avril, Tithi Biswas

Advances in Radiation Oncology · 2024-01 · 9 (1) · 101313

DOI: 10.1016/j.adro.2023.101313 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advances in Radiation Oncology, 2024-01. Verfasst von Saarang R Deshpande und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, University Hospitals, Seidman Cancer Center, Cleveland, Ohio. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Stereotactic body radiation therapy (SBRT) is considered the standard of care for medically inoperable early-stage non-small cell lung cancer. There is mixed evidence on the prognostic significance of tumor metabolic activity assessed by positron emission tomography combined with computed tomography (PET/CT) using F-18 fluorodeoxyglucose (FDG). The objectives of this study were to evaluate the maximum standardized uptake value (SUVmax) pretreatment and at 3 and 6 months after SBRT for prediction of tumor control and survival outcomes. Methods and Materials: Consecutive patients from a single institution with T12N0M0 non-small cell lung cancer receiving primary treatment with SBRT with pretreatment FDG-PET/CT (n = 163) and follow-up FDG-PET/CT at 3 or 6 months (n = 71) were included. Receiver operator characteristic analysis was performed to dichotomize variables for Kaplan-Meier survival analysis. Multivariate analysis was performed with Cox proportional hazards regression.

Results

Median follow-up was 19 months. For the whole cohort, 1-year and 2-year local control, progression-free survival (PFS), and overall survival (OS) were 95.0% and 80.3%, 87.1% and 75.4%, and 67.0% and 49.6% respectively. The following pre-SBRT SUVmax cutoffs were significant: SUV > 4.0 for distant failure-free survival (adjusted hazard ratio [aHR], 3.33, P = .006), >12.3 for PFS (aHR, 2.80, P = .011), and >12.6 for OS (aHR, 3.00, P = .003). SUVmax decreases of at least 45% at 3 months (aHR, 0.15, P = .018), and 53% at 6 months (aHR, 0.12, P = .046) were associated with improved local failure-free survival.

Conclusions

Pre-SBRT SUVmax cutoffs can predict distant failure, PFS, and OS. At both 3 and 6 months after SBRT, cutoffs for percentage change in SUVmax can potentially stratify risk of local recurrence.

Autor:innen und Institutionen

  • Department of Radiation Oncology, University Hospitals, Seidman Cancer Center, Cleveland, Ohio.
  • School of Medicine, Case Western Reserve University, Cleveland, Ohio.
  • Department of Medicine, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania.
  • Department of Radiation Oncology, Medical College of Georgia, Augusta, Georgia.
  • Division of Cardiothoracic Surgery, University Hospitals Cleveland Medical Center, Seidman Cancer Center, Cleveland, Ohio.
  • Department of Radiology, Nuclear Medicine, University Hospitals, Cleveland, Ohio.

Zitieren

APA

Deshpande, S. R., Podder, T. K., Grubb, W., Zhang, Y., Zheng, Y., Towe, C., Linden, P., Avril, N., & Biswas, T. (2024). Pretreatment and Posttreatment Tumor Metabolic Activity Assessed by FDG-PET/CT as Predictors of Tumor Recurrence and Survival Outcomes in Early-Stage Non-Small Cell Lung Cancer Treated With Stereotactic Body Radiation Therapy. Advances in Radiation Oncology, 9(1), 101313. https://doi.org/10.1016/j.adro.2023.101313

Vancouver

Deshpande SR, Podder TK, Grubb W, Zhang Y, Zheng Y, Towe C, et al. Pretreatment and Posttreatment Tumor Metabolic Activity Assessed by FDG-PET/CT as Predictors of Tumor Recurrence and Survival Outcomes in Early-Stage Non-Small Cell Lung Cancer Treated With Stereotactic Body Radiation Therapy. Advances in Radiation Oncology. 2024;9(1):101313. doi:10.1016/j.adro.2023.101313

BibTeX
@article{Deshpande2024,
  author = {Deshpande, Saarang R and Podder, Tarun K and Grubb, William and Zhang, Yuxia and Zheng, Yiran and Towe, Christopher and Linden, Philip and Avril, Norbert and Biswas, Tithi},
  title = {Pretreatment and Posttreatment Tumor Metabolic Activity Assessed by FDG-PET/CT as Predictors of Tumor Recurrence and Survival Outcomes in Early-Stage Non-Small Cell Lung Cancer Treated With Stereotactic Body Radiation Therapy},
  journal = {Advances in Radiation Oncology},
  year = {2024},
  volume = {9},
  number = {1},
  pages = {101313},
  doi = {10.1016/j.adro.2023.101313}
}
Kostenlos starten →